# Who does Amgen pay? Who are its key suppliers?
Canonical: https://valuechain.wiki/amgen · Facet: suppliers · Updated: 2026-09-04T23:12:09.296557+00:00 · Source: ValueChain.wiki (cited money-flow graph)

**Citable summary**: Amgen's confirmed suppliers/cost counterparties include LigaChem Biosciences plus 3 undisclosed/aggregate relationships. Per the valuechain.wiki graph: 4 cost edges, backed by 2 dated sources, 2 of them primary filings (as of 2026-09-04).

### 아스트라제네카 (테프스피어 협업) (high)
- note: Co-develops TEZSPIRE (tezepelumab). Amgen manufactures and supplies worldwide and books U.S. sales; AstraZeneca leads commercialization outside North America (shared profits and costs). TEZSPIRE FY2025 $1.48B (+52%).
- [confirms] SEC EDGAR (EN, filing, published 2026-02-13) https://www.sec.gov/Archives/edgar/data/318154/000031815426000010/amgn-20251231.htm: "Amgen, as principal, recognizes TEZSPIRE product sales in the United States, and AstraZeneca leads commercialization outside North America. Amgen manufactures and supplies TEZSPIRE worldwide."

### UCB (이베니티 협업) (high)
- note: Co-develops EVENITY (romosozumab). Global development costs and commercialization profits and losses are shared equally. UCB leads commercialization across most of Europe; Amgen books sales in the U.S. and other territories. EVENITY FY2025 $2.10B (+34%).
- [confirms] SEC EDGAR (EN, filing, published 2026-02-13) https://www.sec.gov/Archives/edgar/data/318154/000031815426000010/amgn-20251231.htm: "We are in a collaboration with UCB for the development and commercialization of EVENITY. Global development costs and commercialization profits and losses related to the collaboration are shared equally."

### 제3자 위탁생산 (CDMO) (mid)
- note: Uses third-party contract manufacturers to supplement its own network (Puerto Rico, Rhode Island, Ohio, California, Ireland, Netherlands, Singapore) for both commercial and clinical supply. FY2025 cost of sales $12.04B (34.2% of product sales).
- [confirms] SEC EDGAR (EN, filing, published 2026-02-13) https://www.sec.gov/Archives/edgar/data/318154/000031815426000010/amgn-20251231.htm: "We use third-party contract manufacturers to supplement the capacity or capability of our commercial manufacturing network. FY2025 cost of sales $12,037M."

### 리가켐바이오 (mid)  → /ligachem-biosciences.md
- note: In Dec 2022, signed a deal to license in ADC platform (source-technology) from South Korea's LigaChem Biosciences; the disclosed deal size is part of ~KRW 9.4tn in cumulative milestones.
- [confirms] DART (FSS) (KO, filing, published 2026-03-23) https://dart.fss.or.kr/dsaf001/main.do?rcpNo=20260323001538: "Dec 2022: ADC platform transfer deal with Amgen; disclosed drug-segment milestones total ~KRW 9.4tn."

Reverse side: https://valuechain.wiki/amgen/customers.md · Ripple: https://valuechain.wiki/amgen/ripple.md

---
Full node: https://valuechain.wiki/amgen.md · JSON: https://valuechain.wiki/amgen.json